# Pelthos Targets Xepi Promotion to Current Customers by End of Q1 2027 By John Kim Canonical URL: https://www.tokenpost.com/news/business/55979 Published: 2026-11-12T22:29:06.000Z Updated: 2026-11-12T22:29:06.000Z Section: Business > The company has a separate first-quarter 2027 target for Xepi’s launch. Its proposed merger with Castle Creek Biosciences is expected to close by the end of the quarter, pending approval and other conditions. Pelthos Therapeutics Inc. Chief Commercial Officer Sai Rangarao set an end-of-Q1 2027 target for beginning Xepi promotion to the company’s current customer base, as Pelthos pursues a proposed merger with Castle Creek Biosciences. Rangarao outlined the timing on Nov. 12. Pelthos also has a separate target to launch Xepi in Q1 2027; the promotion plan specifically covers its current customer base. The plan follows Pelthos’ [third-quarter results](), when net product revenue from Zelsuvmi rose 114% from a year earlier to $15.2 million. Pelthos expects the proposed merger with Castle Creek to close by the end of Q1 2027, subject to approval from Castle Creek stockholders and other customary closing conditions. ## Links in this article - [third-quarter results](https://www.tokenpost.com/news/business/55688)